Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

238
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
238
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

516
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
516
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cognitive Decline, Neurologic Involvement, and Neonatal Crisis in <i>ABCC9</i>-Related Intellectual Disability and Myopathy Syndrome.

Neurology. Genetics·2026
Same author

Subunit composition of the KATP channels that modulate contractility of skeletal muscle during fatigue.

The Journal of general physiology·2026
Same author

Cantu syndrome-associated SUR2[H60Y] mutation confers selective gain of function on Kir6.1 ATP-sensitive potassium channels.

The Journal of biological chemistry·2025
Same author

From Selective Permeation to Physiology in Potassium Channels.

Function (Oxford, England)·2025
Same author

Muscle fatigue arising intrinsically from SUR2- but not Kir6.1-dependent gain-of-function in Cantu syndrome mice.

The Journal of general physiology·2025
Same author

PIP2-driven cytoplasmic domain motions are coupled to Kir2 channel gating.

The Journal of general physiology·2025

Related Experiment Video

Updated: Aug 27, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

327

Personalized Therapeutics for KATP-Dependent Pathologies.

Colin G Nichols1

  • 1Center for the Investigation of Membrane Excitability Diseases and Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA;

Annual Review of Pharmacology and Toxicology
|September 28, 2022
PubMed
Summary

ATP-sensitive potassium (KATP) channels link metabolism to electrical activity. While drugs exist for KATP channelopathies, their cross-reactivity limits usefulness, necessitating more specific therapeutic agents.

Keywords:
Cantú syndromeKir6.1Kir6.2SUR1SUR2congenital hyperinsulinismneonatal diabetes

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

450

Related Experiment Videos

Last Updated: Aug 27, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

327
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

450

Area of Science:

  • Molecular Biology
  • Physiology
  • Pharmacology

Background:

  • ATP-sensitive potassium (KATP) channels are ubiquitously expressed, coupling cellular metabolism to electrical activity.
  • These channels assemble from four Kir6 pore-forming subunits and four sulfonylurea receptor (SUR) subunits.
  • Gain- or loss-of-function mutations cause monogenic pathologies, with potential for therapeutic correction.

Purpose of the Study:

  • To review KATP channel physiology, pathology, and pharmacology.
  • To discuss the limitations of current KATP channel drugs due to cross-reactivity.
  • To explore the potential for developing more specific and effective therapeutic agents.

Main Methods:

  • Literature review of KATP channel research.
  • Analysis of existing pharmacological data on KATP channel modulators.
  • Discussion of mutation-associated pathologies and therapeutic strategies.

Main Results:

  • A wide range of monogenic pathologies linked to KATP channel mutations are identified.
  • Current drugs, while effective for specific conditions, exhibit cross-reactivity.
  • This cross-reactivity can lead to drug-induced pathologies and limit therapeutic applications.

Conclusions:

  • KATP channelopathies represent a significant area of study with therapeutic potential.
  • The cross-reactivity of existing drugs poses a challenge for safe and effective treatment.
  • Future research should focus on developing highly selective KATP channel modulators for improved therapeutic outcomes.